Calcii dobesilas monohydricus
This medicine should always be taken exactly as described in this package leaflet for the patient or as directed by a doctor or pharmacist.
Rostil max contains the active substance calcium dobesilate monohydrate, which acts on the capillary endothelium, vein walls, and lymphatic vessels. The medicine reduces capillary permeability, increases their resistance, preventing the formation of exudates and improving microcirculation.
The medicine increases the tension of the vein walls, which prevents the formation of stasis and thrombi in the venous vessels. It enhances collagen synthesis, reduces blood viscosity, and increases its flow through peripheral tissues.
It has a sealing effect on the vessels in the lymphatic system, resulting in reduced swelling, leading to the relief of painful symptoms and a feeling of heaviness in the limbs.
Treatment of symptoms of chronic venous insufficiency of the lower limbs (pain, cramps, feeling of heaviness in the legs, tingling, numbness, swelling, skin changes due to blood stasis), varicose veins of the lower limbs.
Symptomatic treatment of hemorrhoids.
The medicine is indicated for use in adults.
Before starting to take Rostil max, the patient should discuss it with their doctor or pharmacist:
Very rarely, after administration of the medicine, agranulocytosis may occur (see section 4: "Possible side effects"), the symptoms of which may include fever, sore throat, infection in the oral cavity, or other symptoms of an ongoing infection. If these symptoms occur, the patient should consult their doctor.
The medicine should not be used in children and adolescents under 18 years of age.
The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
There are no data on the interaction of calcium dobesilate monohydrate with other medicines.
The medicine should be taken during meals.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Pregnancy
The medicine should not be taken during the first trimester of pregnancy.
The medicine may be used during pregnancy only if the doctor considers it absolutely necessary.
Breastfeeding
The medicine should not be taken during breastfeeding.
The medicine does not affect the ability to drive and operate machinery. If dizziness occurs after taking the medicine, the patient should not drive or operate machinery.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
This medicine should always be taken exactly as described in this package leaflet for the patient or as directed by a doctor or pharmacist. If in doubt, the patient should consult their doctor or pharmacist.
The medicine is for oral use.
Adults: 1 tablet 1-2 times a day (corresponding to a daily dose of 500 mg to 1000 mg).
The medicine should be taken during meals.
Treatment may last from several weeks to several months.
In case of taking a higher dose of the medicine than recommended, the patient should immediately consult their doctor or pharmacist.
The patient should continue taking the medicine without increasing the next dose.
A double dose should not be taken to make up for a missed dose.
If the patient has any further doubts about the use of this medicine, they should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Rarely(occurring in 1 to 10 people out of 10,000):
Very Rarely(occurring in less than 1 person out of 10,000):
These adverse reactions disappear after reducing the dose or discontinuing the medicine.
If any side effects occur, including any side effects not listed in this package leaflet, the patient should inform their doctor or pharmacist.
Side effects can be reported directly to the Department of Post-Marketing Surveillance of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 30°C.
Do not use this medicine after the expiration date stated on the blister pack and carton after:
EXP. The expiration date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste containers. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The medicine is in the form of elongated, oval, biconvex tablets with dimensions of 18.5 mm x 8.5 mm, white or almost white in color.
The package contains 30 or 60 tablets. Aluminum/PVC/PVDC blisters are packed in a cardboard box with a package leaflet.
Aflofarm Farmacja Polska Sp. z o.o.
ul. Partyzancka 133/151
95-200 Pabianice
phone: (42) 22-53-100
Aflofarm Farmacja Polska Sp. z o.o.
ul. Szkolna 31
95-054 Ksawerów
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.